INTRODUCTION

It has been shown that both hypoglycaemia and hyperglycaemia in hospitalized patients are associated with many adverse patient outcomes, including increased length of stay (LOS), higher rates of morbidity and mortality, and higher readmission rates.1,2 Given that 25 to 30% of hospitalized patients have a diagnosis of diabetes, it is important to optimize diabetes care in order to diminish patient morbidity and mortality, and lessen the economic burden.3 In 2017, the estimated national cost of diabetes was $327 billion with an estimated 40.3 million inpatient days accrued by those with diabetes.4
An increasing number of studies show that consultations with specialized diabetes teams among hospitalized patients with diabetes resulted in a lower LOS, although these studies have all had fairly small patient populations.\textsuperscript{5–8} The effects of specialized diabetes teams on readmission rates, however, are less clear. One study in Spain found no difference in readmission rates with or without inclusion of a specialized diabetes team in the patients’ care.\textsuperscript{8} On the other hand, a retrospective study comparing hospitalized patients cared for by a specialized diabetes team had significantly lower readmission rates when compared to patients cared for by a primary service team only.\textsuperscript{5} Further, another retrospective study showed a reduction in composite morbidity among hospitalized patients with diabetes if a consultation by a specialized diabetes team was provided.\textsuperscript{9} Given the limited evidence and the importance of diabetes care, a call to action was published in 2013 that outlined the need for further studies to evaluate morbidity, mortality, glycaemic control, and other outcomes in this patient population.\textsuperscript{3} However, due to the increasing evidence of the effectiveness of utilizing dedicated diabetes teams, current guidelines from the American Diabetes Association (ADA) recommend consulting a specialized diabetes team for hospitalized patients with diabetes when possible.\textsuperscript{13}

Our aim was to look at a much larger patient population and to evaluate the impact of a diabetology consultation on LOS in patients with diabetes who were admitted to the general medicine service.

2 | METHODS

Our study was a retrospective analysis of an electronic medical record (EMR) from a large hospital in the northeastern United States, which is an academic teaching institution, including an Internal Medicine residency programme and an Endocrinology, Diabetes and Metabolism fellowship programme. We collected hospital records for all stays between 2013 and 2018 for patients who were at least 18 years of age with either a diagnosis of diabetes in the patient’s medical record or a diagnosis of diabetes from one of the hospital network’s primary care professional sites 12 months prior to the inpatient event on the general internal medicine service. Patients admitted to the general medicine service are primarily cared for by a teaching team consisting of an attending physician, a resident, an intern and medical students, although a smaller subset of patients may be admitted and cared for by an advanced practice provider. Inpatient diabetology consultations (IDCs) are able to be called at any time, and patients are typically seen by an Endocrinology, Diabetes and Metabolism fellow and a supervising attending physician. Inpatient stays for pregnant women were excluded from the sample (n = 21 007). The sample was further limited to those patients with a stay of more than 48 hours (n = 2933) because our key independent variable was IDCs within the first 48 hours. We also excluded those with at least 1 day in the intensive care unit (n = 1383) given that our institution typically employs protocolized insulin infusions for most critically ill individuals, which does not require an IDC. These exclusions resulted in a final sample of 11 477 inpatient hospital events.

We utilized the EMR to access information about demographics, severity of illness (SOI), risk of mortality (ROM), readmissions and information about consultations with a diabetologist. We used the time stamp of the diabetology consult note creation to calculate the time from admission. In order to evaluate and control for severity of diabetes in this analysis, we calculated an average point of care blood glucose test (POC BG) based on those reported during the inpatient stay. Since the number of POC BGs varied, our average POC BG calculation used data from up to the first 10 POC BGs only.

We measured the effect of IDCs within the first 48 hours of admission on: (a) total LOS, measured in days from admission to discharge from the hospital; (b) complications, measured by unexpected inpatient events and (c) 30-day all cause readmissions. We also measured the effect of IDCs at any point during patients’ hospitalizations on these outcomes. We controlled for patient characteristics: age, gender, SOI, ROM, BMI, average POC BG and any diabetology consultation prior to admission to the inpatient medical unit. LOS equations were estimated using a Poisson model while the probability of complications and the probability of readmissions were estimated using Probit models; for the Probit models, the coefficients represent changes in days, while the Probit coefficients are marginal probabilities. All analyses were performed using Stata 15.

3 | RESULTS

Only 3% of the hospital stays we examined had an IDC within 48 hours of hospital admission (Table 1). Those inpatient stays that received an IDC tended to be for patients that were younger or had higher average POC BG scores. Further, only 7.42% of the hospital stays received an IDC at any time during their hospital admission (n = 825).

Table 2 displays the results of the Poisson regression analysing LOS. When compared to the mean LOS for all inpatient stays reviewed in this study, an IDC within 48 hours of admission led to a 1.56 day shorter average LOS that was statistically significant (P < .001). LOS was reduced by nearly half a day for females compared to males (P = .043) and decreased as individuals aged (P < .001). As the level of SOI and ROM increased, LOS is significantly longer. Average POC BG values, BMI and having a consult prior to hospital admission did not significantly change LOS for patients with diabetes in the general internal medicine unit.

Table 3 shows that IDCs had no statistically significant effect on the rate of inpatient complications (P = .167). Female patients had a 1.0% lower chance of complications compared to males (P = .017). Patients with level 4 SOI at admission were 4.2% more likely to experience complications during the hospital stay compared to those admitted with a SOI at level 1 (P = .002); SOI levels
2 and 3 were not statistically significant. There was a significant increase in the likelihood of complications for each ROM level increase. Patients admitted with an ROM equal to 4 experienced a 3.4% higher rate of complications compared to patients with a ROM equal to level 1 \((P = .001)\). The likelihood of complications increased as a patient’s average POC BG value increased \((P = .028)\). BMI, age and diabetology consultation prior to the hospital admission did not significantly impact a patient’s likelihood of experiencing complications.

The probability of a readmission decreased for those with IDCs within 48 hours of admission, but not statistically significantly (Table 4). The probability of any readmission increased for those with an ROM at level 2 by 5.8% and by nearly 7.7% compared to those at level 1 \((P < .001\) and \(P < .001\), respectively). The probability of readmission was 1.6% higher for women when compared to men \((P = .025)\). SOI level, average POCT value, BMI and diabetology consultation prior to admission did not significantly change the probability of readmission.

Patients who received an IDC at any time during their hospitalization compared to those who never received a consult had a significantly longer LOS by 3.16 days \((P < .001\) and \(P < .001\), respectively). The rate of complications was also significantly increased by 2.2% in those who received an IDC consult at any time \((P < .0001)\). The probability of readmission for those with IDCs at any time during their hospitalization was increased by 0.29%, although this was not significant \((P = .731)\).

4 | DISCUSSION

This study showed that among hospitalized patients with diabetes admitted to the internal medicine service, a consultation with diabetology within the first 48 hours of admission reduced the average LOS by 1.56 days. This reduced LOS was only significant if the IDC occurred within the first 48 hours of admission, with a significantly increased LOS among patients who received a consult at any time during their hospitalization, suggesting an optimal time for the initial consultation. Patients who received an IDC within 48 hours also had a slightly lower readmission rate, although this was not statistically significant.

With increasing evidence on the effectiveness of specialized diabetes teams in the hospital setting, the current ADA guidelines recommend a consultation with a specialized diabetes team for all hospitalized patients with diabetes. Prompt IDCs during patients’ hospitalizations are thought to allow for better inpatient glycaemic control and education earlier in the hospitalization to prevent dysglycaemia and complications. This concept is not new, with a similar,
although older, retrospective study showing that the effectiveness of a diabetes care team in reducing LOS was time dependent, with the earliest IDCs time receiving the largest reduction in LOS. IDCs later in patients’ hospitalizations often occur in more ill patients or as a result of complications, which could explain why patients who received an IDC at any time during their hospitalization had both a significantly increased LOS and rate of complications.

In addition to the positive impact of this reduction in LOS on a patient’s quality of life, the economic impact of this reduction in LOS needs to also be considered. One of the largest contributors to the overall cost of diabetes is this population’s higher utilization of inpatient services, which was estimated to cost $69.7 billion in 2017 with 40.3 million inpatient days. Specifically, at our institution, the average total medical charges per day among medicine

---

**Table 2** Poisson regression evaluating the change in length of stay (LOS) for diabetic patients during an inpatient stay on a general internal medicine unit

|                          | Change in LOS (d) | Standard Error | 95% Confidence Limits | P value |
|--------------------------|-------------------|----------------|-----------------------|---------|
| Diabetology Consult in 48 h | −1.56             | 0.38           | 2.30                  | −0.82              | .000    |
| Age (per year older)     | −0.09             | 0.01           | −0.10                 | −0.07              | .000    |
| Female gender            | −0.43             | 0.21           | −0.84                 | −0.01              | .043    |

**Severity of Illness at Admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| Level 2                | −0.2%         | 0.9%           | −1.9%                 | 1.5%    | .838    |
| Level 3                | 1.4%          | 0.9%           | 0.5%                  | 3.2%    | .145    |
| Level 4                | 4.2%          | 1.3%           | 1.6%                  | 6.8%    | .002    |

**Risk of Mortality at Admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| Level 2                | 1.4%          | 0.6%           | 0.3%                  | 2.6%    | .015    |
| Level 3                | 1.9%          | 0.7%           | 0.6%                  | 3.2%    | .004    |
| Level 4                | 3.4%          | 1.0%           | 1.3%                  | 5.5%    | .001    |

**Average POC BG**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 0.0%                   | 0.0%          | 0.0%           | 0.0%                  | 0.0%    | .028    |

**BMI**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 0.0%                   | 0.0%          | 0.0%           | 0.0%                  | 0.0%    | .777    |

**Consultation prior to admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 2.7%                   | 4.1%          | 5.4%           | 10.7%                 | .516    |

---

**Table 3** Marginal effects of complications during an inpatient stay among a diabetic population on the general internal medicine between 2013 and 2018

|                          | % point change | Standard error | 95% Confidence Limits | P value |
|--------------------------|---------------|----------------|-----------------------|---------|
| Diabetology Consult in 48 h | −1.7%         | 1.2%           | −4.0%                 | 0.7%    | .167    |
| Age (per year older)     | 0.0%          | 0.0%           | 0.0%                  | 0.0%    | .150    |
| Female gender            | −1.0%         | 0.4%           | −1.7%                 | −0.2%   | .017    |

**Severity of Illness at Admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| Level 2                | −0.2%         | 0.9%           | −1.9%                 | 1.5%    | .838    |
| Level 3                | 1.4%          | 0.9%           | 0.5%                  | 3.2%    | .145    |
| Level 4                | 4.2%          | 1.3%           | 1.6%                  | 6.8%    | .002    |

**Risk of Mortality at Admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| Level 2                | 1.4%          | 0.6%           | 0.3%                  | 2.6%    | .015    |
| Level 3                | 1.9%          | 0.7%           | 0.6%                  | 3.2%    | .004    |
| Level 4                | 3.4%          | 1.0%           | 1.3%                  | 5.5%    | .001    |

**Average POC BG**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 0.0%                   | 0.0%          | 0.0%           | 0.0%                  | 0.0%    | .028    |

**BMI**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 0.0%                   | 0.0%          | 0.0%           | 0.0%                  | 0.0%    | .777    |

**Consultation prior to admission**

|                        | % point change | Standard error | 95% Confidence Limits | P value |
|------------------------|---------------|----------------|-----------------------|---------|
| 2.7%                   | 4.1%          | 5.4%           | 10.7%                 | .516    |
The 30-day readmission rate has become an important metric of quality healthcare. The Centers for Medicare and Medicaid Services established the Hospital Readmission Reduction Program (HRRP), which looks at 30-day readmission rates as a surrogate of quality healthcare and reduces payments to hospitals if they have high readmission rates. Interestingly, hospital readmission rates have significantly decreased since the implementation of HRRP, although it is unclear of the specific mechanism. Further, it is known that patients with diabetes have higher 30-day readmission rates when compared to patients without diabetes, although there has been no defined intervention to date that has been able to improve this phenomenon. One study found a slightly lower readmission rate among those who received a consult within the first 48 hours although it was not statistically significant. 30-day readmission rates remain an important outcome that needs further studies to determine ways to reduce this among patients with diabetes.

To our knowledge, this is the largest study to examine the effectiveness of an IDC on LOS in hospitalized patients with diabetes; however, it has several limitations. Our study is a retrospective analysis performed at one academic institution that cares for the population of Vermont and Northern New York and the results may not be generalizable to other hospital systems and populations. Additionally, we only looked at patients admitted to the general medicine service, which does not take into account the complexity and variety of medical conditions of patients on surgery and other services. Future aims are to look at these other services, as well as subpopulations of patients, including those receiving tube feeds or total parenteral nutrition, to evaluate the impact of IDC in these populations. Although patients receiving tube feeds or total parenteral nutrition were not excluded, the majority of these patients reside on surgical services which were not included; however, these patients require careful diabetes management given their changing nutritional status, making this an interesting patient population we hope to evaluate in further studies. Going forward, we also hope to obtain prospective data on IDCs and their impact not only on LOS but also complications, 30-day readmission rates, and other important outcomes.

This study found that IDCs within the first 48 hours for patients with diabetes admitted to the general medicine service significantly reduced the LOS by 1.56 days. However, IDCs occurred in only a small minority of patients with diabetes, and less than half of the IDCs occurred within 48 hours of admission. This provides an important area to improve diabetes care in the hospital and potentially reduce economic costs.

ACKNOWLEDGEMENTS
We would like to acknowledge Rebecca Aksdal for assistance in editing of the manuscript.

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

AUTHOR’S CONTRIBUTION
KHS: study conception/design, data analysis, writing, editing and revising of manuscript. AA and CD: study conception/design, data analysis, writing, editing and revising of manuscript.
acquisition, writing and editing of manuscript. JJS: study conception/design, data analysis, editing of manuscript.

DATA AVAILABILITY STATEMENT
Our data are not available for sharing given it contains confidential patient information, but is stored on a secure server should access be needed.

ORCID
Kelsey H. Sheahan https://orcid.org/0000-0001-7223-0911

REFERENCES
1. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119-1131. https://doi.org/10.2337/dc09-9029
2. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16-38. https://doi.org/10.1210/jc.2011-2098
3. Draznin B, Gilden J, Golden SH, et al. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care. 2013;36(7):1807-1814. https://doi.org/10.2337/dc12-2508
4. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928. https://doi.org/10.2337/dc18-0007
5. Bansal V, Mottalib A, Pawar TK, et al. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. BMJ Open Diabetes Res Care. 2018;6(1):e000460. https://doi.org/10.1136/bmjdrsc-2017-000460
6. Flanagan D, Moore E, Baker S, Wright D, Lynch P. Diabetes care in hospital–the impact of a dedicated inpatient care team. Diabet Med. 2008;25(2):147-151. https://doi.org/10.1111/j.1464-5491.2007.02326.x
7. Levetan CS, Salas JR, Wilets IF, Zumoff B. Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes. Am J Med. 1995;99(1):22-28. https://doi.org/10.1016/s0002-9343(99)80100-4
8. Puig J, Supervia A, Marquez MA, Flores J, Cano JF, Gutierrez J. Diabetes team consultation: impact on length of stay of diabetic patients admitted to a short-stay unit. Diabetes Res Clin Pract. 2007;78(2):211-216. https://doi.org/10.1016/j.diabres.2007.03.010
9. Wang YJ, Seggelke S, Hawkins RM, et al. Impact of glucose management team on outcomes of hospitalizaron in patients with Type 2 diabetes admitted to the medical service. Endocr Pract. 2016;22(12):1401-1405. https://doi.org/10.4158/EP161414.OR
10. Wadhera RK, Yeh RW, Joynt Maddox KE. The hospital readmissions reduction program - time for a reboot. N Engl J Med. 2019;380(24):2289-2291. https://doi.org/10.1056/NEJM1901225
11. Ferro EG, Secemsky EA, Wadhera RK, et al. Patient readmission rates for all insurance types after implementation of the hospital readmissions reduction program. Health Aff (Millwood). 2019;38(4):585-593. https://doi.org/10.1377/hlthaff.2018.05412
12. Ostling S, Wyckoff J, Ciarkowski SL, et al. The relationship between diabetes mellitus and 30-day readmission rates. Clin Diabetes Endocrinol. 2017;3(3).
13. American Diabetes Association. 15. Diabetes care in the hospital: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S193-S202. https://doi.org/10.2337/dc20-S015

How to cite this article: Sheahan KH, Atherly A, Dayman C, Schnure J. The impact of diabetology consultations on length of stay in hospitalized patients with diabetes. Endocrinol Diab Metab. 2021;4:e00199. https://doi.org/10.1002/edm2.199